Table 5 Hematologic response rates and... | American Society of Hematology

Table 5

Hematologic response rates and toxicity of CTD, thalidomide, and intermediate-dose chemotherapy regimens in AL amyloidosis

Study	Regimen	No. of patients	Hematologic summated partial and complete response rates, %	Grade 3 or greater toxicity, %	Treatment-related mortality, %
Dispenzieri et al * (2004)¹¹	Low-dose thalidomide	18	Nil	17	NR
Dispenzieri et al* (2003)⁹	Thalidomide (full dose)	12	Nil	50	NR
Seldin et al* (2003)¹⁰	Thalidomide (full dose)	16	5	25	NR
Palladini et al (2005)¹²	Thalidomide/dexamethasone	31	48	65	NR
Goodman et al (2005)⁵	VAD†	229	61	—	5
Goodman et al (2004)⁶	IDM‡	144	54	—	12
Sanchorawala et al (2005)²⁸	SCT§	66	88	—	14
Present study	CTD or CTDa	75	74	32	4

Study	Regimen	No. of patients	Hematologic summated partial and complete response rates, %	Grade 3 or greater toxicity, %	Treatment-related mortality, %
Dispenzieri et al * (2004)¹¹	Low-dose thalidomide	18	Nil	17	NR
Dispenzieri et al* (2003)⁹	Thalidomide (full dose)	12	Nil	50	NR
Seldin et al* (2003)¹⁰	Thalidomide (full dose)	16	5	25	NR
Palladini et al (2005)¹²	Thalidomide/dexamethasone	31	48	65	NR
Goodman et al (2005)⁵	VAD†	229	61	—	5
Goodman et al (2004)⁶	IDM‡	144	54	—	12
Sanchorawala et al (2005)²⁸	SCT§	66	88	—	14
Present study	CTD or CTDa	75	74	32	4

NR indicates not reported; —, not tested.

FLC responses not assessed.

Vincristine, Adriamycin, dexamethasone.

Intravenous intermediate-dose melphalan (25 mg/m²).

Autologous stem cell transplantation.